Review: Cost Effectiveness Analysis And Its Implementation Regarding Hypertension Treatment
DOI:
https://doi.org/10.59188/eduvest.v4i11.1420Keywords:
Hypertension, Cost-Effectiveness Analysis (CEA), Angiotensin Receptor Blocker (ARB), Calcium Channel Blocker (CCB)Abstract
Healthcare financing involves the management of various efforts to mobilize, allocate, and spend health funds to ensure the implementation of health development aimed at achieving the highest possible level of public health. Hypertension, a non-communicable disease (NCD) continues to evolve and poses a serious public health issue and leads to an increasing health financing burden. Health Social Security Agency (BPJS) indicated direct medical costs of hypertension IDR 3 trillion in 2017 and 2018. The variety of first-line antihypertensive combinations due to the numerous recommended first-line antihypertensive combinations in various guidelines highlights the importance of pharmacoeconomic studies to determine the most cost-effective combination. This review article aims to further discuss the implementation of the CEA method as a basis for treatment selection or decision-making regarding hypertension treatment. The nifedipine 60 mg and candesartan 32 mg combination is deemed the best, achieving a blood pressure reduction of 23,8/16,5 mmHg (p<0,01) compared to placebo and monotherapy reductions of 5,3/6,7 mmHg. Additionally, the nifedipine GITS - candesartan combination reduces vasodilator side effects incidence to 18,3% compared to 23,6% for nifedipine monotherapy, including a lower incidence of headaches (5,5% vs. 11%).
References
Albright, R. H. (2024). A Primer on Cost - Effectiveness Analysis. 41, 313–321.
Alzarea, A. I., Khan, Y. H., Alanazi, A. S., Butt, M. H., Almalki, Z. S., Alahmari, A. K., Alsahali, S., & Mallhi, T. H. (2022). Barriers and Facilitators of Pharmacoeconomic Studies: A Review of Evidence from the Middle Eastern Countries. International Journal of Environmental Research and Public Health, 19(13). https://doi.org/10.3390/ijerph19137862
Brandão, S. M. G., Rocca, H.-P. B.-L., Lima, A. C. P. de, & Bocchi, E. A. (2023). A review of cost-effectiveness analysis. 42(August).
Casmuti, & Fibriana, A. I. (2023). Kejadian Hipertensi di Wilayah Kerja Puskesmas Kedungmundu Kota Semarang Casmuti. Higeia Journal of Public Health Research and Development, 7(1), 123–134. http://journal.unnes.ac.id/sju/index.php/higeia
Davari, M., Sorato, M. M., Kebriaeezadeh, A., & Sarrafzadegan, N. (2022). Cost-effectiveness of hypertension therapy based on 2020 International Society of Hypertension guidelines in Ethiopia from a societal perspective. PLoS ONE, 17(8 August), 1–23. https://doi.org/10.1371/journal.pone.0273439
Esh, H., Agabiti, E., France, M. A., Uk, A. D., Germany, F. M., Kerins, M., Germany, R. K., France, S. L., Uk, G. Y. H. L., Uk, R. M., Poland, K. N., Germany, R. E. S., Tsioufis, C., France, V. A., & France, I. D. (2018). 2018 ESC / ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Cardiology ( ESC ) and the European Society of. https://doi.org/10.1097/HJH.
Fadhilah, H., & Sari, V. Y. P. (2019). Beban ekonomi yang ditanggung pasien dan keluarga akibat penyakit stroke : Studi literatur. Journal of Community Medicine and Public Health, 35(6), 193–197.
Fernandez, I. S. (2023). Journal of the Neurological Sciences Understanding cost effectiveness in neurology ´ n S a Iv a. 455(September).
Heroweti, J., & Rokhmawati, I. (2023). Analisis Efektivitas Biaya Kombinasi CCB-ACEI dan CCB-ARB pada Pasien Hipertensi dengan Penyerta DM Tipe II. Jurnal Mandala Pharmacon Indonesia, 9(1), 94–99. https://doi.org/10.35311/jmpi.v9i1.311
Indonesian Society Of Hipertension. (2019). Penatalaksanaan hipertensi 2019.
Indrayathi, P. A. (2021). Bahan Ajar Economic Evaluation in Health Care. Current Clinical Pharmacology, 7(4), 1–33.
Keifer, G., & Effenberger, F. (2022). Pengantar Ekonomi Kesehatan. Angewandte Chemie International Edition, 6(11), 951–952.
Kemenkes RI. (2019). Hari Hipertensi Dunia 2019 : “Know Your Number, Kendalikan Tekanan Darahmu dengan CERDIK.” In Kementrian Kesehatan Republik Indonesia (p. 1). http://p2ptm.kemkes.go.id/kegiatan-p2ptm/pusat-/hari-hipertensi-dunia-2019-know-your-number-kendalikan-tekanan-darahmu-dengan-cerdik
Kemenkes RI. (2022). Profil Kesehatan Indonesia 2021.
Kjeldsen, S. E., Sica, D., Haller, H., Cha, G., Gil-Extremera, B., Harvey, P., Heyvaert, F., J.Lewin, A., Giuseppe, V., & Mancia, G. (2014). Nifedipine plus candesartan combination increases blood pressure control regardless of race and improves the side effect profile: DISTINCTrandomized trial results. Journal of Hypertension 2014, 32:2488–2498, 32, 2488–2498. https://doi.org/10.1097/HJH.0000000000000331
Liu, J., Bu, X., Wei, L., Wang, X., Lai, L., Dong, C., Ma, A., & Wang, T. (2021). Global burden of cardiovascular diseases attributable to hypertension in young adults from 1990 to 2019. Journal of Hypertension, 39(12), 2488–2496. https://doi.org/10.1097/HJH.0000000000002958
Mulianingsih, B. R. N., Endarti, D., & Widayanti, A. W. (2021). Biaya Langsung dan Tidak Langsung pada Penyakit Hipertensi: Narrative Review. Jurnal Surya Medika, 7(1), 99–106. https://doi.org/10.33084/jsm.v7i1.2326
Park, C., Wang, G., Durthaler, J. M., & Fang, J. (2017). Cost-effectiveness Analyses of Antihypertensive Medicines: A Systematic Review. American Journal of Preventive Medicine, 53(6), S131–S142. https://doi.org/10.1016/j.amepre.2017.06.020
Tonin, F. S., Aznar-lou, I., Pontarolo, R., & Fernandez-llimos, F. (2021). Principles of pharmacoeconomic analysis : the case of pharmacist-led interventions. 19(1), 1–10.
Wicaksono, B. ., Wibowo, Sugiyanto, & Hasana, A. R. (2023). Cost Effectiveness Analysis Amlodipin dan Nifedipin pada Pasien Hipertensi Rawat Inap di Rumah Sakit Panti Waluya. Jurnal Sain Farmasi, 4(2), 85–92.
Published
Issue
Section
License
Copyright (c) 2024 Dini Nabilah, Santi Purna Sari, Marlina Dewiastuti
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
